| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Disseminated Intravascular Coagulation | 6 | 2022 | 14 | 2.830 |
Why?
|
| Celiac Disease | 4 | 2023 | 8 | 2.630 |
Why?
|
| HLA Antigens | 5 | 2021 | 50 | 2.270 |
Why?
|
| Tissue Donors | 4 | 2021 | 17 | 2.190 |
Why?
|
| Blood Coagulation Tests | 9 | 2022 | 23 | 2.140 |
Why?
|
| Kidney Transplantation | 4 | 2021 | 42 | 2.110 |
Why?
|
| Humans | 63 | 2024 | 14077 | 2.110 |
Why?
|
| Histocompatibility Testing | 5 | 2023 | 26 | 1.880 |
Why?
|
| Antibodies, Viral | 5 | 2022 | 266 | 1.840 |
Why?
|
| Blood Coagulation | 5 | 2022 | 29 | 1.680 |
Why?
|
| Antibodies | 3 | 2023 | 25 | 1.640 |
Why?
|
| Clinical Laboratory Techniques | 4 | 2020 | 56 | 1.590 |
Why?
|
| Immunoglobulin G | 4 | 2022 | 220 | 1.580 |
Why?
|
| HIV Infections | 15 | 2023 | 4946 | 1.440 |
Why?
|
| Automation, Laboratory | 3 | 2020 | 13 | 1.430 |
Why?
|
| Waiting Lists | 2 | 2019 | 8 | 1.270 |
Why?
|
| South Africa | 25 | 2023 | 7312 | 1.240 |
Why?
|
| Neoplasms | 2 | 2022 | 141 | 1.180 |
Why?
|
| Cardiovascular Diseases | 3 | 2023 | 235 | 1.110 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 8 | 1.010 |
Why?
|
| Hemostatics | 2 | 2022 | 17 | 0.990 |
Why?
|
| Sensitivity and Specificity | 9 | 2022 | 380 | 0.980 |
Why?
|
| Retrospective Studies | 9 | 2022 | 767 | 0.970 |
Why?
|
| Male | 25 | 2022 | 6489 | 0.960 |
Why?
|
| Female | 26 | 2023 | 8751 | 0.950 |
Why?
|
| Immunoassay | 2 | 2022 | 28 | 0.950 |
Why?
|
| Middle Aged | 14 | 2022 | 3425 | 0.910 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 128 | 0.910 |
Why?
|
| Hemoglobins | 2 | 2022 | 40 | 0.910 |
Why?
|
| Autoimmunity | 1 | 2023 | 5 | 0.860 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2023 | 20 | 0.860 |
Why?
|
| Adult | 19 | 2022 | 5664 | 0.850 |
Why?
|
| Biomarkers | 7 | 2023 | 322 | 0.840 |
Why?
|
| Esophageal Neoplasms | 1 | 2022 | 26 | 0.830 |
Why?
|
| Point-of-Care Systems | 2 | 2020 | 88 | 0.820 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2022 | 5 | 0.820 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 7 | 0.810 |
Why?
|
| Virus Diseases | 1 | 2023 | 55 | 0.800 |
Why?
|
| Apoptosis | 1 | 2022 | 39 | 0.800 |
Why?
|
| Quality Assurance, Health Care | 2 | 2019 | 43 | 0.800 |
Why?
|
| Duodenum | 1 | 2021 | 2 | 0.770 |
Why?
|
| Gliadin | 1 | 2021 | 2 | 0.770 |
Why?
|
| Tertiary Care Centers | 2 | 2022 | 78 | 0.770 |
Why?
|
| Histocompatibility | 1 | 2021 | 1 | 0.750 |
Why?
|
| Organ Transplantation | 1 | 2021 | 2 | 0.750 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 39 | 0.750 |
Why?
|
| Freezing | 1 | 2020 | 6 | 0.730 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 3 | 0.730 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 56 | 0.730 |
Why?
|
| Enoxaparin | 1 | 2020 | 11 | 0.730 |
Why?
|
| Anaphylaxis | 1 | 2020 | 1 | 0.730 |
Why?
|
| Food Hypersensitivity | 1 | 2020 | 2 | 0.730 |
Why?
|
| Pandemics | 4 | 2021 | 280 | 0.720 |
Why?
|
| Immunologic Tests | 1 | 2020 | 6 | 0.710 |
Why?
|
| Anticoagulants | 1 | 2020 | 51 | 0.710 |
Why?
|
| Anemia | 1 | 2020 | 41 | 0.700 |
Why?
|
| Serologic Tests | 1 | 2020 | 26 | 0.700 |
Why?
|
| Betacoronavirus | 1 | 2020 | 51 | 0.690 |
Why?
|
| Aged | 9 | 2022 | 1650 | 0.650 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 70 | 0.640 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2019 | 4 | 0.640 |
Why?
|
| Blood Platelets | 4 | 2022 | 30 | 0.640 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 102 | 0.630 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 44 | 0.630 |
Why?
|
| Risk Factors | 7 | 2021 | 1431 | 0.620 |
Why?
|
| Thrombosis | 4 | 2022 | 47 | 0.600 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 29 | 0.600 |
Why?
|
| Platelet Activation | 2 | 2021 | 17 | 0.590 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 210 | 0.580 |
Why?
|
| Specimen Handling | 1 | 2018 | 103 | 0.580 |
Why?
|
| Kidney Diseases | 1 | 2017 | 38 | 0.550 |
Why?
|
| Aged, 80 and over | 4 | 2022 | 449 | 0.530 |
Why?
|
| Thromboplastin | 2 | 2012 | 9 | 0.490 |
Why?
|
| Young Adult | 7 | 2022 | 2357 | 0.470 |
Why?
|
| Flow Cytometry | 4 | 2022 | 65 | 0.420 |
Why?
|
| Child | 6 | 2023 | 2180 | 0.410 |
Why?
|
| Point-of-Care Testing | 3 | 2022 | 68 | 0.400 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 4 | 0.400 |
Why?
|
| P-Selectin | 1 | 2012 | 7 | 0.400 |
Why?
|
| Alleles | 2 | 2023 | 134 | 0.400 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2021 | 16 | 0.380 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 4 | 2021 | 19 | 0.380 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2022 | 150 | 0.370 |
Why?
|
| Cytokines | 2 | 2023 | 107 | 0.370 |
Why?
|
| Fibrinogen | 2 | 2022 | 10 | 0.350 |
Why?
|
| Prothrombin Time | 2 | 2022 | 15 | 0.350 |
Why?
|
| Graft Rejection | 2 | 2021 | 14 | 0.340 |
Why?
|
| Quality Control | 2 | 2020 | 27 | 0.330 |
Why?
|
| Adolescent | 6 | 2021 | 2858 | 0.300 |
Why?
|
| Thrombelastography | 1 | 2007 | 6 | 0.300 |
Why?
|
| Platelet Aggregation | 1 | 2007 | 12 | 0.300 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2007 | 12 | 0.300 |
Why?
|
| Aspirin | 1 | 2007 | 15 | 0.300 |
Why?
|
| Graft Survival | 2 | 2021 | 40 | 0.280 |
Why?
|
| Comorbidity | 2 | 2018 | 184 | 0.270 |
Why?
|
| Seroepidemiologic Studies | 3 | 2021 | 104 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2023 | 168 | 0.250 |
Why?
|
| Cell Proliferation | 2 | 2022 | 43 | 0.230 |
Why?
|
| Feasibility Studies | 2 | 2021 | 95 | 0.230 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 243 | 0.230 |
Why?
|
| Haplotypes | 2 | 2021 | 119 | 0.220 |
Why?
|
| HIV | 3 | 2023 | 380 | 0.220 |
Why?
|
| Cell Cycle | 1 | 2022 | 4 | 0.210 |
Why?
|
| Cell Survival | 1 | 2022 | 45 | 0.210 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 70 | 0.210 |
Why?
|
| Lactate Dehydrogenases | 1 | 2022 | 4 | 0.210 |
Why?
|
| Hemolysis | 1 | 2022 | 7 | 0.210 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 7 | 0.210 |
Why?
|
| Chemokine CX3CL1 | 1 | 2022 | 2 | 0.210 |
Why?
|
| Diet, Gluten-Free | 1 | 2022 | 2 | 0.210 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2022 | 3 | 0.210 |
Why?
|
| Acute-Phase Proteins | 1 | 2022 | 14 | 0.210 |
Why?
|
| Annexin A5 | 1 | 2022 | 2 | 0.210 |
Why?
|
| Necrosis | 1 | 2022 | 7 | 0.210 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2022 | 61 | 0.200 |
Why?
|
| Immunity | 1 | 2022 | 10 | 0.200 |
Why?
|
| Immunogenetics | 1 | 2022 | 1 | 0.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 47 | 0.190 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 10 | 0.190 |
Why?
|
| HLA-DQ Antigens | 1 | 2021 | 8 | 0.190 |
Why?
|
| Transplant Recipients | 1 | 2021 | 6 | 0.190 |
Why?
|
| Oligonucleotides | 1 | 2021 | 19 | 0.190 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 24 | 0.190 |
Why?
|
| Prevalence | 3 | 2021 | 1149 | 0.190 |
Why?
|
| Prognosis | 1 | 2022 | 197 | 0.190 |
Why?
|
| Donor Selection | 1 | 2021 | 7 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 6 | 0.190 |
Why?
|
| Isoantibodies | 1 | 2021 | 15 | 0.190 |
Why?
|
| Child, Preschool | 4 | 2021 | 1675 | 0.190 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 183 | 0.180 |
Why?
|
| Cryopreservation | 1 | 2020 | 4 | 0.180 |
Why?
|
| China | 1 | 2021 | 21 | 0.180 |
Why?
|
| Vaccination | 1 | 2023 | 347 | 0.180 |
Why?
|
| Monocytes | 2 | 2012 | 27 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 6 | 0.180 |
Why?
|
| Hematologic Tests | 1 | 2020 | 11 | 0.180 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 367 | 0.180 |
Why?
|
| Coronavirus | 1 | 2021 | 14 | 0.180 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2020 | 9 | 0.180 |
Why?
|
| Inflammation | 1 | 2021 | 103 | 0.170 |
Why?
|
| Risk Assessment | 1 | 2021 | 217 | 0.170 |
Why?
|
| RNA, Viral | 1 | 2021 | 303 | 0.170 |
Why?
|
| Prothrombin | 1 | 2019 | 8 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 7 | 0.170 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2019 | 9 | 0.170 |
Why?
|
| Clinical Laboratory Services | 1 | 2019 | 4 | 0.170 |
Why?
|
| Infant | 3 | 2021 | 2145 | 0.160 |
Why?
|
| Immunoturbidimetry | 1 | 2019 | 3 | 0.160 |
Why?
|
| von Willebrand Diseases | 1 | 2019 | 8 | 0.160 |
Why?
|
| Blood Chemical Analysis | 1 | 2019 | 14 | 0.160 |
Why?
|
| Laboratories | 1 | 2019 | 44 | 0.160 |
Why?
|
| von Willebrand Factor | 1 | 2019 | 21 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 2 | 2021 | 11 | 0.160 |
Why?
|
| Antithrombins | 1 | 2018 | 2 | 0.160 |
Why?
|
| Centrifugation | 1 | 2018 | 2 | 0.160 |
Why?
|
| Partial Thromboplastin Time | 1 | 2018 | 13 | 0.160 |
Why?
|
| Mutation | 1 | 2019 | 299 | 0.150 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 17 | 0.150 |
Why?
|
| Temperature | 1 | 2018 | 56 | 0.150 |
Why?
|
| Warfarin | 1 | 2018 | 15 | 0.150 |
Why?
|
| Virulence Factors | 1 | 2018 | 18 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2018 | 55 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 251 | 0.150 |
Why?
|
| Survival | 1 | 2017 | 1 | 0.140 |
Why?
|
| Time Factors | 1 | 2018 | 503 | 0.140 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 532 | 0.140 |
Why?
|
| Disease Management | 1 | 2017 | 73 | 0.140 |
Why?
|
| Immunophenotyping | 2 | 2015 | 24 | 0.130 |
Why?
|
| Lymphoma | 1 | 2015 | 4 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2022 | 654 | 0.130 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2012 | 10 | 0.120 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2012 | 7 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 11 | 0.100 |
Why?
|
| HLA-DR Antigens | 1 | 2012 | 13 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2012 | 23 | 0.100 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 40 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 320 | 0.100 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 263 | 0.090 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2010 | 3 | 0.090 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 3 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2010 | 4 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 5 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2010 | 23 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 40 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 145 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2021 | 1410 | 0.080 |
Why?
|
| Reference Values | 1 | 2007 | 64 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2007 | 64 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 25 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2023 | 50 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 124 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1377 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 25 | 0.060 |
Why?
|
| alpha-2-Antiplasmin | 1 | 1985 | 1 | 0.060 |
Why?
|
| Blood Coagulation Disorders | 1 | 1985 | 6 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2021 | 464 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 12 | 0.060 |
Why?
|
| Kinetics | 1 | 2024 | 65 | 0.060 |
Why?
|
| Paraffin Embedding | 1 | 2023 | 2 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 6 | 0.060 |
Why?
|
| Hormones | 1 | 2023 | 9 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2023 | 13 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 2023 | 14 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 1 | 2023 | 17 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2023 | 32 | 0.060 |
Why?
|
| Gene Expression | 1 | 2023 | 43 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 44 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2022 | 25 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 11 | 0.050 |
Why?
|
| Mean Platelet Volume | 1 | 2021 | 3 | 0.050 |
Why?
|
| Platelet Count | 1 | 2021 | 14 | 0.050 |
Why?
|
| Age Distribution | 1 | 2021 | 106 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2021 | 2 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2021 | 19 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2021 | 11 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 42 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2022 | 148 | 0.050 |
Why?
|
| Sentinel Surveillance | 1 | 2021 | 110 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2020 | 5 | 0.050 |
Why?
|
| Epitopes | 1 | 2021 | 97 | 0.050 |
Why?
|
| Legg-Calve-Perthes Disease | 1 | 2000 | 1 | 0.040 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2000 | 4 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 655 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 11 | 0.040 |
Why?
|
| Blood Coagulation Factors | 1 | 1999 | 16 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 82 | 0.040 |
Why?
|
| Mediastinal Neoplasms | 1 | 1998 | 2 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 1998 | 5 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 168 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 939 | 0.040 |
Why?
|
| Viral Load | 1 | 2022 | 808 | 0.040 |
Why?
|
| Anemia, Dyserythropoietic, Congenital | 1 | 1996 | 1 | 0.030 |
Why?
|
| Lymphoma, T-Cell | 1 | 1996 | 4 | 0.030 |
Why?
|
| Algorithms | 1 | 2015 | 105 | 0.030 |
Why?
|
| Polycythemia Vera | 1 | 1994 | 1 | 0.030 |
Why?
|
| Neprilysin | 1 | 1994 | 2 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1994 | 2 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1994 | 3 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 128 | 0.030 |
Why?
|
| Pregnancy | 1 | 2019 | 1815 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2011 | 3 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2011 | 5 | 0.020 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2010 | 3 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2010 | 5 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2010 | 14 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 60 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 77 | 0.020 |
Why?
|
| Flagellin | 1 | 2009 | 3 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2009 | 79 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 37 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 186 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 1969 | 15 | 0.020 |
Why?
|
| Virus Replication | 1 | 2009 | 87 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 1985 | 3 | 0.020 |
Why?
|
| Tranexamic Acid | 1 | 1985 | 13 | 0.020 |
Why?
|
| Antithrombin III | 1 | 2000 | 1 | 0.010 |
Why?
|
| Protein S | 1 | 2000 | 3 | 0.010 |
Why?
|
| Leukocyte Common Antigens | 1 | 1998 | 3 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1998 | 19 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1998 | 21 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1998 | 26 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1998 | 18 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1998 | 63 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1998 | 137 | 0.010 |
Why?
|
| Erythroblasts | 1 | 1996 | 1 | 0.010 |
Why?
|
| Endothelium | 1 | 1973 | 1 | 0.010 |
Why?
|
| Platelet Adhesiveness | 1 | 1973 | 1 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1973 | 11 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1973 | 70 | 0.010 |
Why?
|
| Northern Ireland | 1 | 1991 | 1 | 0.010 |
Why?
|
| Data Collection | 1 | 1991 | 86 | 0.010 |
Why?
|
| Micrococcus | 1 | 1969 | 1 | 0.010 |
Why?
|